Seroba Life Sciences

Seroba Life Sciences is a prominent venture capital firm based in Dublin, Ireland, dedicated to investing in breakthrough healthcare technologies. The firm's core focus spans the broader life sciences sector, including innovative companies in biotech, medtech, and digital health. Seroba aims to identify and support ventures that are developing novel therapies, diagnostics, and medical devices designed to address significant unmet medical needs and improve patient outcomes.

The firm typically engages with companies from early-stage to growth-stage, often leading or co-leading Series A and B rounds. Seroba is known for its hands-on approach, providing not only capital but also strategic guidance and operational support to its portfolio companies. A significant milestone for the firm was the closing of its fourth fund, Seroba BioVentures IV, in 2023, which secured €150 million (approximately $162 million) in commitments. This fund reinforces their capacity to back promising European life sciences ventures.

Seroba's initial investment checks typically range from €3 million to €10 million (approximately $3.24 million to $10.8 million), with the potential for follow-on investments that can bring total capital deployed per company up to €20 million. This flexible approach allows them to support companies through various growth phases. The firm has a strong track record of identifying and nurturing successful ventures, exemplified by the acquisition of their portfolio company Inflazome by Roche for an upfront payment of €380 million (approximately $410 million) plus milestones. This exit highlights Seroba's ability to generate significant returns for its limited partners while contributing to the advancement of medical innovation.

While headquartered in Ireland, Seroba maintains a pan-European investment scope, actively seeking opportunities across the continent. Their team comprises professionals with deep scientific, medical, and financial expertise, enabling them to conduct thorough due diligence and provide valuable insights to their portfolio companies. This blend of scientific understanding and investment acumen positions Seroba as a key player in the European life sciences venture capital landscape.